|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
Human T cell immunity against tumour antigens
If you have a question about this talk, please contact Prof. Jim Kaufman.
Host: Peter Goon (email@example.com)
My group studies human T cells and their potential role in therapy of pre-malignant and malignant diseases. Our main focus has been on human papillomaviruses (HPV) that are associated with the development of cervical cancer. We developed techniques to study HPV specific T cells responses for a series of phase I/II trials with a candidate therapeutic vaccine (TA-HPV). We demonstrated that systemic T cell responses against HPV were relatively weak, both in vaccinated and non-vaccinated patients. Nevertheless we could isolate and grow T cell clones from rare populations, that could kill cancer cells in vitro. This suggests a therapeutic potential for HPV specific T cells but new approaches will be required to induce large numbers of efficacious T cells. We are currently defining new T cell targets based on proteins that are abnormally expressed in cancer. These targets may be applicable to a broad range of human cancers, particularly those caused by oncogenic viruses.
This talk is part of the Immunology in Pathology series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
Other listsCambridge Science Festival Turing Centenary Conference Materials Chemistry Research Interest Group
Other talksAre there limits to evolution? (Conference 25 & 26 September 2014) Succulents in South Africa Are we star dust or nuclear waste? Astonomy lecture Inferno XXIV, Purgatorio XXIV, Paradiso XXIV (SP Wednesday Workshop) - TBC Imaging experience dependent structural plasticity